Braskem S.A. (BAK), Latin America's largest petrochemical producer and the Americas' biggest maker of thermoplastic resins and polyolefins, suffered one of its sharpest one-day declines on record Monday. The American depositary receipts fell roughly 44.12%, or about $0.75, to near $0.95, after closing the prior session at $1.70. The selloff was triggered by the company's weekend disclosure of competing restructuring proposals for its approximately $11 billion debt load, terms that investors quickly recognized would leave existing shareholders with only a small fraction of the company.
The dominant catalyst behind the share plunge was the release of detailed restructuring documents. Under Braskem's own proposal, creditors would convert about $2.8 billion of debt into equity, while controlling shareholders and third parties would backstop part of a $2.25 billion follow-on share offering. The creditors' counterproposal was similar in shape, calling for roughly $1.85 billion in immediate debt-to-equity conversion alongside a $2.25 billion equity raise, with most of it guaranteed upfront.
Either way, the combined new equity and debt conversion totals roughly $4 billion to $5 billion — many times the company's recent market value of around $650 million. Because the shares being created dwarf the entire existing equity base, current holders of BAK would be diluted to a small minority stake. That arithmetic, not the petrochemical cycle, now drives the stock's valuation, and the market repriced the ADRs accordingly.
The dilution concern was compounded by a separate legal front. On October 21, three funds affiliated with hedge fund Bracebridge Capital filed an involuntary Chapter 11 petition against Braskem America Finance Company, a Delaware financing subsidiary that issued roughly $589 million of notes due in 2041. The funds, which say they hold about $272 million of that issue, argue the subsidiary has not been paying debts as they come due.
While the petition targets a financing vehicle rather than the operating company, it signals that not every creditor is willing to wait for a consensual, out-of-court deal. A court-supervised restructuring generally produces a harsher outcome for equity holders than a negotiated settlement, reinforcing the bearish tone in BAK shares.
The move also reflects a steady stream of negative analyst revisions in recent weeks. HSBC downgraded the stock to Hold, UBS cut it to Sell, Citi moved to Sell, and JPMorgan shifted to Neutral, with several firms citing deteriorating petrochemical spreads, leverage, and the risk that restructuring leaves little value for common shareholders. Monday's selling was further amplified by a generally defensive tone across Brazilian financial and energy names ahead of the Federal Reserve's policy decision, although BAK fell far more than the broader market.
Trading volume was elevated as investors reacted to the weekend disclosures, continuing a pattern of heavy turnover that has accompanied each restructuring headline. The decline pushed the stock decisively below its 50-day moving average and toward the lower end of its 52-week range, which spans roughly $1.40 to $5.40. The move diverged sharply from the broader indices, underscoring that this was a company-specific, balance-sheet-driven repricing rather than a broad market correction.
The near-term outlook for BAK hinges on the restructuring negotiations. The parties are working toward an agreement on key terms, with deadlines extending into late October and a final approval window around November 22. A deal that emerges sooner could stabilize sentiment, but only if its terms preserve meaningful value for current holders — a bar that the disclosed proposals, as structured, do not clearly clear.
Investors will also watch the company's next earnings release, expected November 12, for updates on petrochemical spreads, cash flow, and any progress toward finalizing a restructuring plan. Lingering environmental liabilities tied to the Maceió ground-subsidence case, estimated in the billions of dollars, remain a further overhang. Until the capital structure is repaired, volatility in the shares is likely to persist.
Tickeron's Trending AI Robots page highlights a curated selection of automated trading bots that are currently performing best in live market conditions. Tickeron offers hundreds of AI-driven bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see which strategies are leading the market today.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BAK declined for three days, in 306 of 352 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In 61 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for BAK turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
BAK moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for BAK entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAK advanced for three days, in 187 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
BAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (-0.035) is slightly lower than the industry average of (1.147). P/E Ratio (-0.078) is within average values for comparable stocks, (3.243). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (3.769). BAK's Dividend Yield (2.475) is considerably higher than the industry average of (0.195). P/S Ratio (0.051) is also within normal values, averaging (0.578).
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of petrochemicals and other related products
Industry ChemicalsMajorDiversified